Podcast
A Prescription for Fair Drug Pricing
Hosted by instituteforclinicalandeconomicreview · EN
By Jason L. Crowell, MD Jerome H. Grossman MD Graduate Fellow, Harvard Kennedy School Neurologist, Beth Israel Deaconess Medical Center; Steve Pearson, Founder and President, ICER, Lecturer, Department of Population Medicine, Harvard Medical School
9episodes
Episodes
Newest firstAll episodes
How doctors can be a part of the solution
Dec 21, 202000:16:20Tap to summarizeWhat can physicians do in their hospitals and communities to advocate for fair drug prices? What questions should we ask our patients to assess for financial toxicity? In the final episode of the season, we discuss the steps doctors can be taking now to help solve the drug pricing problem.
Transcribe →What else makes a drug “valuable”?
Dec 14, 202000:20:14Tap to summarizeIf we only look at the benefits that a drug provides to those patients who take it, we may underestimate its value by ignoring the benefits it provides to the broader healthcare system. In episode 7, we reveal some of the other reasons that can make a drug more valuable than first meets the eye.
Transcribe →Cost-effectiveness 101
Dec 7, 202000:26:10Tap to summarizeIf a “fair” price rewards the benefit a drug provides, how do we quantify those benefits—both to the patient and, more broadly, to society? Cost-effectiveness analysis is the tool we can use to quantify a drug’s benefit in a way that can be compared across treatments.
Transcribe →Who sets a drug’s price, and how do we know it’s fair?
Nov 30, 202000:22:22Tap to summarizeIn episode 5, we review the variety of approaches one might take to settle on what the “fair” price of a drug should be. The most logical solution to this problem is to price the value—set a drug’s price commensurate with the clinical benefits it provides.
Transcribe →What’s in it for me? Incentives for making new drugs
Nov 23, 202000:27:24Tap to summarizeWhat motivates a drug manufacturer to create a drug in the first place? How do firms stretch the limits of these incentives? In episode 4, we discuss how the “ecosystem” of drug development in the US has led to truly remarkable innovation but also runaway drug prices.
Transcribe →From Pharma to the Medicine Cabinet: Who Manages the Drugs?
Nov 16, 202000:25:23Tap to summarizeDrugmakers, pharmacies, wholesale distributors, physicians, pharmacy benefit managers—the world of prescription drugs can seem extraordinarily complex. In episode 3, we disentangle this spider’s web and answer the question: who decides how much our patients pay at the pharmacy?
Transcribe →Tradeoffs
Nov 9, 202000:15:26Tap to summarizeWhenever we choose to spend on one thing instead of another, we pay an opportunity cost. And, just like in life, healthcare is an either/or decision. Patients face decisions about how to spend their money on healthcare, just like insurance companies and governments must decide how to spend their finite dollars on healthcare.
Transcribe →Financial Toxicity
Nov 2, 202000:16:58Tap to summarizeIn the first episode of the series, we discuss the problem of skyrocketing drug prices and the harmful effects they have on our patients. Not only must patients decide what their medications are worth to them, but payers introduce barriers that limit patients’ access to care. More broadly, we also review the ways that drug prices affect all of our society, via rising insurance premiums and taxes.
Transcribe →COMING SOON: A Prescription for Fair Drug Pricing
Oct 15, 202000:04:09Tap to summarizeIn a new podcast series from the Institute for Clinical and Economic Review (ICER), neurologist Dr. Jason Crowell sits down with ICER’s President Dr. Steve Pearson to pry open the black box of US drug pricing and to wrestle with each of the financial and ethical tensions that undergird our current medical infrastructure. A must-listen for physicians, patients, and policymakers who are concerned that prescription drugs not only can have health side effects, but financial side effects, too.
Transcribe →